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Biochemistry
NF-cB protein purification from bovine spleen: Nucleotide
stimulation and binding site specificity
(K immunoglobulin light chain gene/enhancer/interleukin 2/human immunodeficiency virus)
MICHAEL J. LENARDO, ANNA KUANG, ANN GIFFORD, AND DAVID BALTIMORE
Whitehead Institute for Biomedical Research, Cambridge, MA 02142, and Department of Biology, Massachusetts Institute of Technology,
Cambridge, MA 02139
Contributed by David Baltimore, August 10, 1988
ABSTRACT The activity of the enhancer for the K immu-
noglobulin light chain gene critically depends on the presence
in the nucleus of the NF-KB protein. We purified NF-KB over
50,000-fold and identified two protein species, 42 and 44 kDa,
that could be eluted and renatured from a sodium dodecyl
sulfate/polyacrylamide gel to give specific DNA-binding ac-
tivity. Binding ofthe purified bovine NF-KB as well as that from
human and murine B- or T-lymphoid cell extracts was dra-
matically stimulated by nucleoside triphosphates. This effect
distinguished NF-KB from a related factor, H2-TF1. Purified
NF-KB interacted efficiently with regulatory sequences that
function during either B- or T-lymphocyte activation, including
the human immunodeficiency virus enhancer and a NF-KB
binding site we detected in the interleukin 2 enhancer.
The differentiation of B lymphocytes is a well-characterized
example of changes in gene activity during progression
through a cell lineage (1). One important event is expression
of the immunoglobulin light chain gene. NF-KB, a DNA-
binding protein that recognizes a 10-base-pair (bp) enhancer
sequence, is crucial for expression of the K light chain gene
(2-6). Only mature B cells and exceptional T cell lines
express NF-KB binding constitutively (2), but binding can be
induced in other cells by agents such as lipopolysaccharide
(LPS), cycloheximide, and phorbol esters (3).
Recently, an NF-KB-like factor was shown to play an
important role in the expression of the interleukin 2 (IL-2)
receptor a chain during activation of T lymphocytes (7-9).
The enhancer of human immunodeficiency virus (HIV)-1, a
T-lymphotropic virus, also binds an NF-KB-like factor (10-
14). These results may indicate that NF-KB participates in
expression of genes during activation of both B and T
lymphocytes. Alternatively, there is evidence indicating that
a distinct factor with some characteristics of NF-KB may
exist in T cells (13).
A different nuclear factor, H2-TF1, has a binding site with
close sequence similarity to that ofNF-KB. H2-TF1 is present
in lymphoid and nonlymphoid cells and plays a role in major
histocompatibility complex (MHC) class I gene expression
(15, 16). Recently, a clone was selected by the H2-TF1
binding site from a Agtll expression library (17). The binding
characteristics of this clone led to the proposal that H2-TF1
may be a constitutively active form of NF-KB (16, 17). Thus,
it is important to compare biochemical features of these
binding proteins to determine their relationship.
We purified NF-KB over 50,000-fold to a set of two protein
species of 42 and 44 kDa. Nucleoside triphosphates were
found to dramatically increase the binding of purified NF-KB
as well as unpurified binding protein from human and mouse
lymphoid cell extracts. By contrast, H2-TF1 was not stimu-
lated by nucleoside triphosphates. Highly purified NF-KB
interacted with regulatory sequences expressed during either
B- or T-lymphocyte activation. The most efficient binding we
detected was to a site in the IL-2 gene enhancer. Thus the
same NF-KB protein is likely to regulate genes during
activation of both B and T lymphocytes.
MATERIALS AND METHODS
Preparation of Nuclear Extracts. Fresh bovine spleen was
pressed through a 60-mesh screen and erythrocytes were
lysed in 4 vol of0.83% NH4Cl, pH 7.2. Nuclear extracts were
prepared at 40C according to Dignam et al. (18). All buffers
included leupeptin at 0.3 ,ug/ml, 5 mM phenylmethylsulfonyl
fluoride, and antipain at 0.3 /tg/ml. Typically, 1.5 kg of spleen
yielded 3.6 g of crude nuclear extract. Protein was measured
by Bradford assay (19).
Chromatographic Fractionation. Sephacryl S-300 (Phar-
macia) (1 liter in a 5 x 60 cm column) was equilibrated with
buffer D [20 mM Hepes, pH 7.9/0.2 mM EDTA/0.5 mM
dithiothreitol/0.1 M KCI/20% (vol/vol) glycerol]. Portions
(190 ml) of nuclear extract (600 mg of protein) were precip-
itated with 60 g of ammonium sulfate (5o0 saturation),
resuspended in 50 ml of buffer D, and fractionated at 0.06
column volumes per hour. Washed phosphocellulose (250 ml
in a 5 x 25 cm column) was equilibrated with buffer D. The
Sephacryl S-300 active fraction (750 ml; 200 mg of protein)
was applied, washed with 1250 ml ofbuffer D, and eluted with
a 1-liter gradient from 0.1 to 1.0 M KCI in buffer D.
Hydroxylapatite chromatography using a Bio-Gel 100 x 7.5
mm HPHT column (Bio-Rad) was previously described (20).
The phosphocellulose peak was dialyzed against buffer A (50
mM KHPO4, pH 7.5/1 mM dithiothreitol/0.01% Nonidet
P-40/0. 1 mM phenylmethylsulfonyl fluoride/0.01 mM
CaCl2/10% glycerol), applied to the HPHT column at a flow
rate of 0.5 ml/min, washed with 22.5 ml of buffer A, and
eluted with a 15-ml gradient from 0 to 1 M NaCl in buffer A.
DNA affinity chromatography was performed according to
Kadonaga and Tjian (21), using an oligonucleotide containing
22 base pairs from the K enhancer (5'-CAGAGGGGACTT-
TCCGAGAGGC-3') with TCGA 5' overhanging ends. The
column contained 1.2 nmol of binding sites per ml of
Sepharose gel. Chromatography was carried out in buffer Q
(20 mM Hepes, pH 7.9/100 mM NaCl/0.2 mM EDTA/0.5
mM dithiothreitol/0.05% Nonidet P-40/20% glycerol). The
load was mixed with poly(dI-dC) (Pharmacia) at 25 .Lg/mg on
ice for 15 min and applied dropwise to the column. The
column was washed with 10 column volumes of buffer Q and
step eluted with buffer Q containing successively 0.1 M, 0.2
M, 0.3 M, 0.5 M, 0.75 M, 1.0 M, and 2.0 M NaCl. Activity
eluted in the 0.5 M NaCl fraction. When the Escherichia coli
DNA column was used, buffer Q/0.1 M KCl was the loading
buffer and the protein was eluted with a 0.1 to 1.0 M NaCl
Abbreviations: LPS, lipopolysaccharide; IL-2, interleukin 2; HIV,
human immunodeficiency virus; MHC, major histocompatibility
complex; LTR, long terminal repeat.
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gradient in buffer Q. Fractions were analyzed by electropho-
resis on miniature NaDodSO4/polyacrylamide gels (22) and
silver staining (23).
Binding Assays. Mobility shift electrophoresis assay mix-
tures (5) contained 0.25 ng of 32P-labeled DNA fragment
(15,000 cpm), 10mM Tris HCl at pH 7.5, 1 mM dithiothreitol,
1 mM EDTA, 0.5 mM MgCl2, 3 mM GTP (omitted in
experiments in which the amount of added GTP was varied),
and 5% glycerol. Assays of crude fractions used 0.5 ,ug of
poly(dI-dC) and those of affinity fractions used no poly(dI-
dC) but included 1.25 ,ug of bovine serum albumin. The IL-2
receptor a-chain probe was generously provided by S. Cross
and W. Leonard (National Institutes of Health), and the
MHC class I probe (17) was generously provided by H. Singh
(Massachusetts Institute ofTechnology). Competition assays
used the K enhancer oligonucleotide described above or an
oligonucleotide from nucleotides -186 to -210 of the human
IL-2 promoter (5'-CAAAGAGGGATTTCACCTACATCC-
3') (24). Strands were annealed and diluted in 20 mM
Tris HCl, pH 7.6/100 mM NaCl. Methylation interference
analysis (2) and denaturation-renaturation analysis (25) were
performed as described previously.
DNase I footprinting by the procedure of Jones et al. (26)
used either wild-type or mutant versions (7) of a 150-bp Ava
I-Bgl II HXBH2 long terminal repeat (LTR) fragment (pro-
vided by Mark Feinberg, Whitehead Institute) radioactively
labeled at the Ava I site.
RESULTS
Extracts from Bovine Spleen Cells Contain NF-KB. Bovine
spleen nuclear extracts were found to have levels of a binding
activity comparable to those of NF-KB in WEHI 231 murine
B lymphoid tumor cells (Fig. 1, lanes 1 and 2). Interestingly,
the bovine nucleoprotein complex formed with sites from the
MHC class I gene promoter, the HIV-1 LTR, and the IL-2
receptor a-chain promoter (see Fig. 2B and Fig. 5). Mutations
that abrogate murine NF-KB binding also eliminated the
bovine complex (Fig. 1, compare lane 3 to lane 4 and lane 5
to lane 6). The complex was not found in bovine brain,
thymus, or a kidney cell line but could be induced by phorbol
esters (C. Murre, M.J.L., and D.B., unpublished results).
We next examined the close contacts between protein and
DNA by comparing bovine extracts to those from LPS- and
cycloheximide-treated murine 70Z/3 cells in a methylation
interference assay (2, 3). Methylation of three guanines that
interfered with formation of the 70Z/3 complex also partially
or totally interfered with formation of the bovine complex
(Fig. 2A, lanes 2 and 4). On the opposite strand methylation
of three guanines interfered with formation of both the
KB MHC
WT M WT M
.:i
'.
..35
3 4 5 6
FIG. 1. Mobility shift elec-
trophoresis assay of bovine
spleen nuclear extracts. Ten mi-
crograms of protein from either
crude bovine nuclear extracts
(lanes 1 and 3-6) or WEHI 231
murine B cell nuclear extracts
(lane 2) was used with either
wild-type (WT) (lanes 1, 2, and
3) or mutant (M) (lane 4) ver-
sions of the K enhancer binding
site (KB) (5) or with the wild-
type (WT, lane 5) or mutant (M,
lane 6) of the MHC class I bind-
ing site (MHC) (17).
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FIG. 2. Methylation interference and DNase I footprinting
analyses. (A) Methylation interference assay using the K enhancer
site compares bovine extract to 70Z/3 murine pre-B lymphocytes
stimulated with E. coli strain 055:B5 LPS (Difco) and cycloheximide
(2, 3). Lanes 1 and 3 are free probe and lanes 2 and 4 are probe from
the nucleoprotein complex. Dots indicate guanine residues whose
methylation interferes with complex formation. Below is the K
enhancer site with circles around the guanine residues that interfere
with complex formation when methylated. (B) DNase I footprint
with wild-type (HIV) or mutant (hiv) HIV-1 enhancer sequences.
Indicated is the position of the two NF-KB binding motifs and the
limits of the protected region (-80 to -108). Below is shown the
HIV-1 enhancer region with the NF-KB recognition motifs boxed and
arrows indicating the base changes in the mutant sequence (10).
murine and bovine complexes (data not shown). The bottom
of Fig. 2A summarizes the interference pattern. Because of its
specific binding, tissue distribution, phorbol ester inducibil-
ity, and other biochemical properties described below, we
conclude that the identified factor is the bovine homologue of
the murine or human NF-KB protein.
Chromatographic Purification of the NF-KB Binding Pro-
tein. Crude nuclear extract was fractionated by Sephacryl
S-300 chromatography (see Table 1). The active pool was
applied to a P-11 phosphocellulose column and eluted with a
linear KCI gradient from 0.1 to 1.0 M. Binding activity eluted
between 0.4 and 0.6 M KCl. To eliminate contaminants that
1 2
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Table 1. Purification of NF-KB
Total Specific Overall Overall
Protein, Volume, activity, activity, purification, yield,
Step Fraction mg ml units units/mg -fold S
I Nuclear extract 3600 1150 115,000 32 100
II Sephacryl S-300 690 2170 41,000 60 1.9 36
III Phosphocellulose 45 640 37,000 820 26 32
IV Hydroxylapatite 6.2 177 52,000 8,300 260 45
V E. coli DNA 0.9 105 24,000 27,000 840 21
VI NF-KB affinity 0.005 1.0 9,500 1,900,000 59,000 8.3
Activity is given as a relative binding unit, with 1 unit being equivalent to the binding detected in 10 gl of the crude nuclear
extract.
bound to DNA at high salt concentrations, hydroxylapatite
chromatography was used; the activity eluted sharply be-
tween 0.5 and 0.6 M NaCl. Total activity increased, appar-
ently because this step removed an inhibitor of binding.
Finally, a site-specific DNA affinity column using NF-KB
binding sequences from the K enhancer was used (21). In
some preparations, this step was preceded by a nonspecific
E. coli DNA-Sepharose column. Alternatively, nonspecific
competitor DNA was added to the load. Either procedure
provided an additional purification of 50- to 100-fold. A
nearly 60,000-fold purification was obtained with an 8%
recovery (Table 1). Because the yield was 5 ug of protein
from approximately 4 x 1011 spleen cells (after elimination of
erythrocytes), we estimate there are 1500 molecules of
NF-KB per cell.* This suggests NF-KB is a low-abundance
protein in bovine spleen.
Chromatographic fractions were compared by NaDodSO4/
polyacrylamide gel electrophoresis and silver staining. Early
steps yielded complex mixtures of polypeptides (Fig. 3A,
lanes 1-5). By contrast, only three polypeptides, 42, 44, and
55 kDa, were detected in active affinity fractions (Fig. 3A,
compare lane 7 to lanes 6 and 8). Because the 55-kDa species
was also found in an inactive fraction (Fig. 3A, lane 8), it is
likely that either the 42- or the 44-kDa species or both are
responsible for binding.
To establish that the purified proteins contained binding
activity, we excised slices from a preparative NaDodSO4/
*The estimate was based on 60% of the final protein yield being
NF-KB, such that 5(0.60)/0.08 = 40 ,ug maximum theoretical yield.
This is 1 x 10-9 mol or 6 X 1014 molecules from 4 x 10"1 cells or
1500 molecules per cell.
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polyacrylamide gel (shown in Fig. 3A) and eluted the protein.
Eluted material was then denatured, renatured, and assayed
for binding by mobility shift gel electrophoresis. Only the gel
slice containing the 42- and 44-kDa proteins yielded binding
activity; that containing the 55-kDa protein and other slices
did not (Fig. 3B). The renatured complex comigrated with
NF-KB and did not bind the mutant probe, demonstrating that
the 42- and 44-kDa proteins have specific NF-KB binding
activity. These results were consistent with the molecular
weight determination of bovine NF-KB in crude extracts and
with the analysis of partially purified fractions by two-
dimensional electrophoresis (P. Baeuerle, M.J.L., and D.B.,
unpublished results). Glycerol gradient sedimentation sug-
gested that purified bovine NF-KB exists in solution as a
dimer (data not shown).
Nucleoside Triphosphates Stimulate Binding of NF-KB in
Vitro. In testing possible cofactors for binding, we found that
guanosine 5'-triphosphate (GTP) powerfully stimulated the
binding of purified NF-K13. At 3 mM, GTP gave up to a
100-fold stimulation (Fig. 4A, top) but greater amounts
decreased binding. The triphosphate was required, since
GDP, GMP, cGMP, and guanosine 5'-[,8y-imido]triphos-
phate gave little or no effect (Fig. 4A, bottom). Either ATP
or GTP could stimulate binding of NF-KB in crude nuclear
extracts (Fig. 4B). Of particular importance, CEM, a human
T cell line that efficiently replicates HIV, contains a binding
activity specific for NF-KB sites that was markedly stimu-
lated by GTP (Fig. 4B). Further experiments showed that any
of the four standard deoxyribonucleoside triphosphates or
the four ribonucleoside triphosphates increased binding at
similar concentrations (data not shown).
SDS-PAGE GEL SLICE
Load 1 2 3 4 5
WT M WT M WT M WT M WT M WT M
44#
-B
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FIG. 3. PAGE analysis of chromatographic fractions. (A) NaDodSO4 (SDS) polyacrylamide gel stained with silver. One binding unit was
used ofthe crude nuclear extract (lane 1) and the activity peaks from the Sephacryl S-300 (lane 2) and phosphocellulose (lane 3) purified fractions.
Some of the phosphocellulose sample was lost by precipitation in NaDodSO4. Ten binding units were used of hydroxylapatite (lane 4), and E.
coli DNA (lane 5) purified fractions. For NaCl step elutions from the affinity chromatography the 50-pA1 samples are 0.2 M (lane 6), 0.5 M (-450
binding units; lane 7), and 0.75 M (lane 8). At the right are the boundries of gel slices used for denaturation-renaturation. The 42- and 44-kDa
species are indicated by an arrowhead. (B) Mobility shift electrophoresis assay of renatured proteins from gel slices (1-5 as indicated in A) or
the starting material (Load). Probes are the wild-type (WT) or mutant (M) K enhancer binding sites (5). Indicated at the right are the positions
of the bound (B) and free (F) probes.
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FIG. 4. (A) Nucleoside triphosphate stimulation of NF-KB binding. Each panel shows the nucleoprotein complex formed in the presence
of the millimolar amounts of GTP (top) or GTP and related compounds as indicated (bottom); the free probe is not shown. The top row shows
the complex of 2 til of purified bovine NF-KB with the K enhancer probe (5) (NF-KB); 12.5 ,ug of 38B9 murine pre-B lymphoma nuclear extract
with the NF-KE2 probe (5) (KE2); 7.5 ,ug of HeLa human cervical carcinoma nuclear extract with the activator protein 1 probe (27) (AP-1); 3
Ag ofWEHI-231 murine B lymphoma nuclear extract with the immunoglobulin enhancer octanucleotide probe (5) (OCTA); and 15 ,ug of a mouse
erythroleukemia line (MEL) nuclear extract with the H2-TF1 binding site (17) (H2-TF1). Complexes are indicated by arrowheads. The bottom
row shows titration of GTP, guanosine 5'-diphosphate (GDP), guanosine 5'-monophosphate (GMP), guanosine 3',5'-cyclic monophosphate
(cGMP), or guanosine 5'-[P3,y-imido]triphosphate (GMP-PNP), using 2 ,ul of purified bovine NF-KB with the K enhancer probe (5). (B) Adenosine
5'-triphosphate (ATP) and GTP stimulation was carried out with the millimolar amount of nucleotide indicated above each lane. Crude nuclear
extracts from 70Z/3 murine pre-B lymphoma stimulated with LPS and cycloheximide (70Z/3-LPS/CYC) as previously described (3) (2.25 ,ug
per lane) or from CEM human T cells (27) (6 ,ug per lane) were used with the K enhancer probe (5).
We next tested nucleotide stimulation of H2-TF1 binding
(16, 17). No stimulation of H2-TF1 binding was seen at any
concentration of GTP (Fig. 4A, top), indicating a clear
biochemical difference between it and NF-KB. In addition,
several other DNA-binding factors could not be stimulated to
bind (Fig. 4A, top).
Purified NF-KB Recognizes Multiple Gene Regulatory Se-
quences Involved in Lymphocyte Activation. We qualitatively
and quantitatively assessed the binding ofthe purified protein
to control sequences of genes expressed during B- or T-
lymphocyte activation. NF-KB binding was qualitatively
assessed by using the HIV LTR enhancer in DNase I
footprinting. The footprint was identical to that observed
with extracts from activated T lymphocytes and clearly
different from that seen with nonlymphoid extracts (Fig. 2B;
see ref. 14). To quantitatively assess binding, the interactions
of NF-KB with the K enhancer, MHC class I promoter, and
IL-2 receptor a-chain promoter sequences were tested in a
NF- KB IL-2R MHC
Comp.: 0 .5 2 8 0 .5 2 8 0 .5 2 8
(ng)
competition assay. Each of the binding sites was used as a
radiolabeled probe and a double-stranded K enhancer oligo-
nucleotide was added as unlabeled competitor. In each case,
the competitor impaired binding at 8 ng (Fig. 5). Competition
for binding to the K enhancer was slightly more prominent at
lower concentrations, suggesting that the B-cell-derived fac-
tor does not bind better but may in fact bind less well to the K
site. Nonspecific oligonucleotides had no effect (data not
shown).
Since NF-KB has been clearly implicated in the expression
of the IL-2 receptor, we investigated whether NF-KB might
coordinately regulate the IL-2 gene (7-9, 29). The enhancer
of the human gene contains a sequence (5'-AGGGATTT-
CAC-3') from position -195 to -205 that has significant
homology to the NF-KB motif (24, 29). This sequence is
exactly conserved between the mouse and human genes (30),
NFK B OCTA AP-1 H2-TF1
- 0.52616-.5 2 8 16 - 0.52 8 16 - 6-0.5 2 8 16
1 2 3 4 5 6 7 8 9 10 11 12 13
FIG. 5. Competition binding assay ofNF-KB cognate motifs from
different genes. Assays used the K enhancer probe (5) (NF-KB, lanes
1-5), the IL-2 receptor a-chain promoter probe from a subclone of
the region of -228 to -298 (28) (IL-2R, lanes 6-9), or the H2-TF1
binding site probe from the MHC class I promoter (17) (MHC, lanes
10-13). All assays included 2 ,ul ofpurified bovine NF-KB except lane
1 (4) and the NF-KB oligonucleotide competitor in the nanogram
amounts shown above each lane.
ig
_i=
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FIG. 6. Competition binding assay using sequences from the IL-2
gene promoter. Protein extracts and probes are the same as those
described in the legend to Fig. 4 for purified NF-KB (NF-KB; lanes
1-5), the immunoglobulin enhancer octanucleotide factors (OCTA;
lanes 6-10), the AP-1 factor (AP-1; lanes 11-15), and the H2-TF1
factor (H2-TF1; lanes 16-20). Annealed IL-2 oligonucleotides were
added in the nanogram amounts indicated at the top; a dash indicates
that only buffer was added.
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and a DNase I footprint over this region was found by using
extracts from activated T cells (29). We found that a double-
stranded oligonucleotide containing the IL-2 site competed
for NF-KB efficiently (Fig. 6). This site was more than 4-fold
better than the K enhancer motif (compare Fig. 6 with Fig. 5).
The oligonucleotide did not compete for several other DNA-
binding proteins (Fig. 6). Especially important is the fact that
the H2-TF1 factor did not compete, suggesting H2-TF1 has
less than 1/30th the affinity for the IL-2 sequence that NF-KB
has. Interestingly, a second nucleoprotein complex with the
H2-TF1 probe of faster mobility competed equivalently to
NF-KB (Fig. 6), but this has not been studied further.
DISCUSSION
The purpose of our study was to determine the biochemical
features and binding specificity of purified NF-KB. We
devised a purification scheme that identified two polypep-
tides, 42 and 44 kDa, the smaller of which may be a
proteolytic product of the larger protein. Binding of these
polypeptides was dramatically stimulated in vitro by nucle-
oside triphosphates. Moreover, purified NF-KB reproduced
the DNase I footprint obtained with T-lymphoid extracts on
the HIV-1 enhancer and bound tightly to regulatory sites
from genes expressed in both B and T lymphocytes.
At least five factors have been identified that can bind to
sequences related to the NF-KB motif: NF-KB, H2-TF1,
KBF-1, enhancer binding protein 1 (EBP-1) and HIV en-
hancer binding protein 86 (HIVEN86) (2, 13, 16, 20, 31). Of
these, only NF-KB has been clearly shown to be tissue
restricted (to B lymphocytes) in its constitutive expression.
HIVEN86 appears to be closely related to NF-KB in its
binding specificity and inducibility in lymphoid cells. EBP-1,
KBF-1, and H2-TF1 are all found in nonlymphoid cells and
may be identical. Previously, it was proposed that H2-TF1 is
a constitutive form of the NF-KB protein (16, 17). However,
differences between H2-TF1 and NF-KB were noted in both
their contacts with DNA and their relative preference of
binding sites (15, 16). We now extend this comparison by
showing that a site in the IL-2 gene is recognized over 30-fold
better by NF-KB than by H2-TF1. Also, nucleoside triphos-
phates greatly stimulate NF-KB binding but not H2-TF1
binding. The magnitudes of these differences suggest that
NF-KB and H2-TF1 arise from different gene products. A
precedent in this regard is the ubiquitously expressed nuclear
factor Al (NF-A1) protein and the lymphoid-specific NF-A2
protein, which bind an octamer motif identically but are
encoded by different genes (32).
The dramatic stimulation of binding by nucleotides was
unique to NF-KB among several DNA-binding proteins
tested. The only other report of such a phenomenon of which
we are aware is the increase in binding of simian virus 40
tumor (T) antigen to DNA caused by ATP (33). The nucle-
otide effect in that case was quite different in that only ATP
and dATP were effective. Since nucleoside triphosphates
stimulated highly purified NF-KB, the nucleotides may di-
rectly interact with the protein. This interaction could cause
a conformational change, which may increase the affinity of
binding or the rate at which complex is formed. The effect
depended on the nucleoside triphosphates and was not seen
with the nonhydrolyzable imido analogue of GTP, indicating
that hydrolysis of the nucleotide could be involved. The
stimulation of NF-KB by nucleoside triphosphates may rep-
resent another means of regulating DNA-binding activity.
The participation of the NF-KB protein, as our data
suggest, in both B- and T-cell activation is a regulatory
puzzle. What specifies certain genes, such as immunoglob-
ulin K gene, to take part in -the B-cell response and others,
such as the IL-2 gene and its receptor, to be expressed during
the T-cell response? Though expression of the IL-2 receptor
a chain (Tac antigen) does occur in some B-lymphocyte lines,
its role in a proliferative response to IL-2 is controversial
(34). Purified NF-KB does not discriminate between B- and
T-cell-specific sites. We believe this means that the inducible
binding activity detected in both B and T cells is due to the
same NF-KB protein. This is supported by our finding that
binding activity in the CEM T-cell line is stimulated by
nucleoside triphosphates. It is also supported by the recent
finding that a human B-lymphocyte protein similar or iden-
tical to NF-KB activates transcription in vitro from the HIV
LTR (35). While induction of binding represents one level of
NF-KB regulation, other events apparently distinguish the T-
and B-lymphocyte response to activation.
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